Certara Announces Pricing of Public Offering of Common Stock

Rhea-AI Summary

Certara, Inc. (Nasdaq: CERT) has announced the pricing of its underwritten public offering of 10 million shares of common stock by existing stockholders at $25.00 per share. The underwriters have a 30-day option to purchase up to an additional 1,500,000 shares. Certara will not receive any proceeds from this offering. The closing is anticipated around March 29, 2021, subject to customary conditions. The offering is managed by Jefferies, Morgan Stanley, and BofA Securities.

Positive

• The offering includes an option for underwriters to purchase an additional 1,500,000 shares, potentially increasing liquidity.
• The participation of leading underwriters may indicate strong market interest.

Negative

• Certara will not receive any proceeds from this offering, which limits potential capital for growth.
• The sale of shares may lead to dilution for existing shareholders.

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders (“the selling stockholders”) at a price to the public of $25.00 per share. Additionally, the selling stockholders have granted the underwriters a 30-day option to purchase up to 1,500,000 additional shares of common stock. Certara is not selling any shares and will not receive any proceeds from the sale of shares in the offering by the selling stockholders. The offering is expected to close on or about March 29, 2021, subject to customary closing conditions.

The offering is being made through an underwriting group led by Jefferies, Morgan Stanley and BofA Securities, who are acting as lead joint book-running managers, and Credit Suisse, Barclays and William Blair, who are acting as joint book-running managers.

A registration statement on Form S-1, including a prospectus, relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering may be made only by means of a prospectus. Copies of the preliminary prospectus may be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 547-6340 or by email at Prospectus_Department@jefferies.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; or BofA Securities, Inc., NC1-004-03-43, Attention: Prospectus Department, 200 North College Street, 3rd Floor, Charlotte, NC 29255, by telephone at (800) 294-1322 or by email at dg.prospectus_requests@bofa.com.

About Certara

Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210324006025/en/

FAQ

What is the price per share for Certara's public offering?

The price per share for the public offering is $25.00.

How many shares are being offered in Certara's public offering?

Certara is offering 10 million shares, with an additional option of 1,500,000 shares for underwriters.

When is the expected closing date for Certara's public offering?

The expected closing date is around March 29, 2021.

Will Certara receive any proceeds from the share offering?

No, Certara will not receive any proceeds from the sale of shares, as the shares are being sold by existing stockholders.

Who are the underwriters for Certara's public offering?

The underwriters include Jefferies, Morgan Stanley, and BofA Securities, among others.